ApeCoin vs Bio Protocol — how do they compare? ApeCoin trades at Rp2,205 (market cap Rp2,19T, Rp118,62M 24h volume), while Bio Protocol trades at Rp439.16 (market cap Rp1T, Rp164,77M 24h volume). The key difference: ApeCoin is far larger — about 2.2× Bio Protocol's market cap, and ApeCoin's circulating supply is 1B / 1B APE (100%) versus 2,3B / 3,3B BIO (69%) for Bio Protocol. Which is the better fit depends on your goals — on Pluang, investors hold ApeCoin for 62 Days and Bio Protocol for 18 Days on average.
| APE | BIO | |
|---|---|---|
Market Cap | Rp2,19T | Rp1T |
Volume (24h) | Rp118,62M | Rp164,77M |
Circulating Supply | 1B / 1B APE (100%) | 2,3B / 3,3B BIO (69%) |
Typical Hold Time | 62 Days | 18 Days |
Signals from Pluang's Aura AI — not financial advice
ApeCoin is trading at Rp2,205 with a market cap of Rp2.19 trillion, showing a fully diluted supply of 1 million tokens. The technical outlook is bearish overall, with moving averages signaling strong selling pressure, though oscillators suggest some bullish momentum. Current price hovers near support at Rp2,204, with resistance at Rp2,233. No major protocol updates or ecosystem developments were noted recently.
The overall outlook is cautious due to bearish technical signals and lack of fundamental catalysts. Key opportunities include potential bounces from support levels, while risks involve continued downward pressure and low liquidity. Investors should monitor for any ecosystem growth or token utility enhancements to shift sentiment.
No Aura AI signal available yet.
What Pluang investors did over the last 30 days
ApeCoin is a decentralized project inspired by Yuga Labs' Bored Ape Yacht Club project. ApeCoin was founded to be used within the burgeoning APE Ecosystem, which is supported by the APE Foundation. The ApeCoin DAO aims to build and maintain the APE Ecosystem in a fair and inclusive way, providing an infrastructure for ApeCoin holders to collaborate through open and permissionless governance processes.
Read more on APE →BIO Protocol enables global communities of scientists, patients, and investors to collectively fund, develop, and co-own new drugs and therapeutics through its network of Biotech Decentralized Autonomous Organizations (BioDAOs). The protocol's innovative approach addresses critical gaps in traditional scientific funding, particularly in areas such as rare diseases, longevity research, and emerging health challenges.
Read more on BIO →